Altimeter Capital, a private equity firm, led a $50m Series C round in Unlearn, an AI company creating digital twins of clinical trial participants that enable smaller, faster studies, with participation from Radical Ventures, Wittington Ventures, Mubadala Capital, Epic Ventures, and Necessary Venture Capital. "Pharmaceutical companies are spending over $100bn a year on clinical research, yet the industry remains skeptical about new technology that has the power to truly transform research. Breaking down these barriers and proving the value of digital twin technology continues to be a main driver for us at Unlearn. And, this round of financing will allow us to not only grow our team but also expand our capabilities into more therapeutic areas to build awareness and prove the value," Charles Fisher, Unlearn Founder and CEO.